Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
Pharmacovigilance01:19

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Consensus on acromegaly complications: an update.

Pituitary·2026
Same author

Pituitary adenoma imaging as a determinant of acromegaly diagnosis and outcomes.

The Journal of clinical endocrinology and metabolism·2026
Same author

Long-term safety and efficacy of pegvisomant monotherapy for acromegaly: final data from the full ACROSTUDY cohort.

Pituitary·2026
Same author

What is the future of acromegaly therapy?

The Journal of clinical endocrinology and metabolism·2026
Same author

Efficacy and safety of once-weekly somatrogon in adults with growth hormone deficiency: a randomized phase 3 study.

Pituitary·2026
Same author

Real world experience with [<sup>68</sup>Ga]PentixaFor PET/CT in Primary Aldosteronism using newly developed harmonized diagnostic criteria.

Frontiers in endocrinology·2026

Related Experiment Videos

Experience from the German pegvisomant observational study.

Christian J Strasburger1, Michael Buchfelder, Michael Droste

  • 1Division of Clinical Endocrinology, Department of Medicine, Campus Mitte, Charité Universitatsmedizin Berlin, Germany. christian.strasburger@charite.de

Hormone Research
|February 7, 2008
PubMed
Summary

The German Pegvisomant Observational Study (GPOS) found pegvisomant effective for acromegaly treatment. This growth hormone receptor antagonist normalized disease activity and improved patient symptoms with a well-tolerated safety profile.

Related Experiment Videos

Area of Science:

  • Endocrinology
  • Pharmacology

Background:

  • The German Pegvisomant Observational Study (GPOS) was initiated following the German marketing authorization of pegvisomant for acromegaly.
  • GPOS is the largest database for pegvisomant-treated patients, representing over 87% of those in Germany.

Purpose of the Study:

  • To document the safety and efficacy of pegvisomant, the first growth hormone-receptor antagonist, in acromegaly patients.
  • To analyze data from 263 patients, most with prior insufficient disease control from other treatments.

Main Methods:

  • The study utilized data from the German Pegvisomant Observational Study (GPOS) database.
  • An interim analysis of 263 patients was performed in August 2006.

Main Results:

  • Pegvisomant treatment normalized disease activity in the majority of patients.
  • Favorable effects on glucose metabolism and improvements in acromegaly signs and symptoms were observed.
  • The safety profile was well-tolerated; transaminase elevations occurred in 16 patients but mostly resolved spontaneously or upon discontinuation.

Conclusions:

  • The GPOS database offers crucial insights into the treatment modalities, safety, and efficacy of pegvisomant for acromegaly.
  • Pegvisomant demonstrates a favorable risk-benefit profile in managing acromegaly.